Rx Loxicom Injectable 5 mg x 20 ml

Loxicom 5mg/ml Solution for Injection For Dogs and Cats Description Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. Each mL of this sterile product for injection contains meloxicam 5.0 mg, alcohol 15%, glycofurol 10%, poloxamer 188 5%, sodium chloride 0.6%, glycine 0.5% and meglumine 0.3%, in water for injection, pH adjusted with sodium hydroxide and hydrochloric acid. Indications Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of postoperative pain and inflammation following orthopaedic and soft tissue surgery. Cats: For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration when administered prior to surgery. Prescription items are Non-Returnable and Non-Refundable. - CAUTIONS/WARNINGS:Warnings Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For IV or SQ injectable use in dogs. All dogs should undergo a thorough history and physical examination before administering any NSAID. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to, and periodically during use of any NSAID in dogs. Owner should be advised to observe their dogs for signs of potential drug toxicity. Precautions Do not use in pregnant or lactating animals. Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and hemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in animals less than 6 weeks of age nor in cats of less than 2kg. The safe use of Loxicom 5 mg/mL Solution for Injection in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating bitches has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders. Safety has not been established for intramuscular (IM) administration in dogs. When administering Loxicom 5 mg/mL Solution for Injection, use a syringe of appropriate size to ensure precise dosing. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or preexisting disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is needed after the administration of the total daily dose of meloxicam oral suspension, a non-NSAID or noncorticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from corticosteroid use or from one NSAID to another in dogs. The use of concomitantly, protein-bound drugs with Loxicom 5 mg/mL Solution for Injection has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of Loxicom 5 mg/mL Solution for Injection has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. The effect of cyclo-oxygenase inhibition and the potential for thromboembolic occurrence or a hypercoagulable state has not been studied. Adverse Reactions Typical adverse reactions of non-steroidal anti-inflammatory drugs NSAIDs such as loss of appetite, vomiting, diarrhea, fecal occult blood, apathy and renal failure have occasionally been reported. In dogs, these adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. In very rare cases anaphylactoid reactions may occur and should be treated symptomatically. Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with the use of meloxicam in cats. If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinarian. For post-operative pain relief in cats, safety has only been documented after thiopental/halothane anaesthesia. If adverse effects occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. Do not use an oral follow-up therapy containing meloxicam or other NSAIDs in cats, as no safe dosage for repeated oral administration has been established. Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Loxicom must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. In the case of overdose symptomatic treatment should be initiated. To report suspected adverse reactions, to obtain a Material Safety Data Sheet, or for technical assistance, call 866-591-5777. Operator warnings: Accidental self-injection may give rise to pain. People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician. Handling and Storage Handling: Avoid contact with eyes, skin and clothing. Do not breathe vapours or mist. Do not ingest. Do not smoke or eat while handling the product. Wash thoroughly after handling. The containers should be stored in their original boxes when not in use. Storage:Store in closed containers in a cool, dry, well-ventilated area, below 25° C and away from oxidisers, heat, sparks and open flame. Protect containers from physical damage and light. Keep container closed when not in use. Do not transfer contents to unlabelled containers. Use only with adequate ventilation. Keep out of reach of children. Pharmaceutical Precautions This veterinary medicinal product does not require any special storage conditions. Shelf-life after first opening the container 28 days. Do not use after the expiration date stated on the carton and the bottle. Dispose of any unused product and empty container in accordance with guidance from your local waste regulation authority. First Aid Measures Inhalation Remove to fresh air. If any signs or syumptoms occur or persist seek mediacl advice. Skin Contact Wash thoroughly with soap and water. Remove contaminated clothing and was before reuse. Eye Contact Immediately flush eyes with copious amounts of water for at least 15 minutes. If irritation persists, seek medical attention. Ingestion Do not induce vomiting. Seek medical attention. - DIRECTIONS:Dosage & Administration Dogs: Single administration of 0.2mg Meloxicam/kg bodyweight (i.e. 0.4ml/10kg). Musculo-skeletal disorders: Single subcutaneous injection. Loxicom 1.5 mg/ml oral suspension may be used for continuation of treatment at a dosage of 0.1 mg Meloxicam/kg bodyweight, 24 hours after administration of the injection. Reduction of post-operative pain (over a period of 24 hours): Single intravenous or subcutaneous injection before surgery, for example at the time of induction of anaesthesia. Cats: Administer a single, one-time subcutaneous dose of Loxicom 5 mg/mL Solution for Injection to cats at a dose of 0.14 mg/lb (0.3 mg/kg) body weight. Use of additional meloxicam or other NSAIDs is contraindicated. (See Contraindications). To ensure accuracy of dosing, the use of a 1 mL graduated syringe is recommended. Contraindications: Cats with known hypersensitivity to meloxicam should not receive Loxicom 5 mg/mL Solution for Injection. Additional doses of meloxicam or other NSAIDs in cats are contraindicated, as no safe dosage for repeated NSAID administration has been established (See Animal Safety). Do not use meloxicam in cats with pre-existing renal dysfunction. For subcutaneous (SQ) injectable use in cats. Do not use IV in cats. Do not administer a second dose of meloxicam. Do not follow the single, one-time dose of meloxicam with any other NSAID. Do not administer meloxicam oral suspension following the single, one-time injectable dose of meloxicam. Particular care should be taken with regard to the accuracy of dosing. Avoid introduction of contamination during use. - INGREDIENTS:Presentation Each ml contains: Meloxicam 5 mg/ml Ethanol, anhydrous 150mg/ml - HEIGHT(INCHES): 1.000 - WIDTH(INCHES):1.000 - LENGTH(INCHES):1.000 Brand: Loxicom Manufacturer: Ingredients: Directions: Cautions: Storage: